104 related articles for article (PubMed ID: 9393585)
1. The administration of paclitaxel without prophylaxis for the prevention of hypersensitivity reactions: is this a rationale and safe therapeutic strategy?
Markman M
J Cancer Res Clin Oncol; 1997; 123(10):531-2. PubMed ID: 9393585
[No Abstract] [Full Text] [Related]
2. [Paclitaxel hypersensitivity reactions in patients with advanced ovarian carcinoma].
Kobierski J; Majdak E; Mielcarek P; Emerich J
Ginekol Pol; 2002 Nov; 73(11):1015-20. PubMed ID: 12722392
[TBL] [Abstract][Full Text] [Related]
3. Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
Bookman MA; Kloth DD; Kover PE; Smolinski S; Ozols RF
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-13-S19-15. PubMed ID: 9427258
[TBL] [Abstract][Full Text] [Related]
4. [New generation of percutaneous coronary intervention: drug-eluting stent].
Yamaguchi T
Nihon Naika Gakkai Zasshi; 2005 Feb; 94(2):362-8. PubMed ID: 15768603
[No Abstract] [Full Text] [Related]
5. Drug-eluting stents: the panacea for restenosis?
Lim MC
Singapore Med J; 2004 Jul; 45(7):300-2. PubMed ID: 15221043
[No Abstract] [Full Text] [Related]
6. [Are drug-coated stents too expensive?].
Kaulen H
Dtsch Med Wochenschr; 2003 Nov; 128(47):2466. PubMed ID: 14658445
[No Abstract] [Full Text] [Related]
7. An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions.
Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
J Cancer Res Clin Oncol; 1999 Jul; 125(7):427-9. PubMed ID: 10394964
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.
Rowinsky EK; Smith L; Wang YM; Chaturvedi P; Villalona M; Campbell E; Aylesworth C; Eckhardt SG; Hammond L; Kraynak M; Drengler R; Stephenson J; Harding MW; Von Hoff DD
J Clin Oncol; 1998 Sep; 16(9):2964-76. PubMed ID: 9738565
[TBL] [Abstract][Full Text] [Related]
9. Risk of severe acute hypersensitivity reactions after rapid paclitaxel infusion of less than 1-h duration.
Tsavaris NB; Kosmas C
Cancer Chemother Pharmacol; 1998; 42(6):509-11. PubMed ID: 9788579
[TBL] [Abstract][Full Text] [Related]
10. Role of substance P in hypersensitivity reactions induced by paclitaxel, an anticancer agent.
Sendo T; Itoh Y; Goromaru T; Hirakawa T; Ishida M; Nakano H; Oishi R
Peptides; 2004 Jul; 25(7):1205-8. PubMed ID: 15245881
[TBL] [Abstract][Full Text] [Related]
11. Guidelines for handling antineoplastic and immunosuppressive drugs.
Watson AD; Peaston AE; Malik R; Swinney GR
Aust Vet J; 1997 Dec; 75(12):868-76. PubMed ID: 9469220
[No Abstract] [Full Text] [Related]
12. Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer.
Kruijtzer CM; Schellens JH; Mezger J; Scheulen ME; Keilholz U; Beijnen JH; Rosing H; Mathôt RA; Marcus S; van Tinteren H; Baas P
J Clin Oncol; 2002 Dec; 20(23):4508-16. PubMed ID: 12454106
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes.
Blum JL; Savin MA; Edelman G; Pippen JE; Robert NJ; Geister BV; Kirby RL; Clawson A; O'Shaughnessy JA
Clin Breast Cancer; 2007 Dec; 7(11):850-6. PubMed ID: 18269774
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review.
Holmes FA
Semin Oncol; 1996 Oct; 23(5 Suppl 11):46-56. PubMed ID: 8893900
[TBL] [Abstract][Full Text] [Related]
15. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies.
Robinson JB; Singh D; Bodurka-Bevers DC; Wharton JT; Gershenson DM; Wolf JK
Gynecol Oncol; 2001 Sep; 82(3):550-8. PubMed ID: 11520154
[TBL] [Abstract][Full Text] [Related]
16. Tapering and discontinuation of glucocorticoid prophylaxis during prolonged weekly to biweekly paclitaxel administration.
Braverman AS; Rao S; Salvatti ME; Adamson B; McManus M; Pierre S
Chemotherapy; 2005 May; 51(2-3):116-9. PubMed ID: 15886470
[TBL] [Abstract][Full Text] [Related]
17. The feasibility of dexamethasone omission in weekly paclitaxel treatment for breast cancer patients.
de Castro Baccarin AL; Irene MN; de Iracema Gomes Cubero D; Luz AS; Castro SN; Sordi R; Móz LES; Del Giglio A
Support Care Cancer; 2019 Mar; 27(3):927-931. PubMed ID: 30069696
[TBL] [Abstract][Full Text] [Related]
18. [Definitive results of a phase I study of a chemotherapy regimen using cisplatin and paclitaxel for non-small cell bronchial cancer].
Sculier JP; Klastersky J
Rev Mal Respir; 1995; 12(6):609-14. PubMed ID: 8677355
[TBL] [Abstract][Full Text] [Related]
19. Randomized, Controlled Trial of Dexamethasone Versus Dexamethasone Plus Hydrocortisone as Prophylaxis for Hypersensitivity Reactions Due to Paclitaxel Treatment for Gynecologic Cancer.
Jeerakornpassawat D; Suprasert P
Int J Gynecol Cancer; 2017 Oct; 27(8):1794-1801. PubMed ID: 28704328
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
